Carparts.Com Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Carparts.Com Inc trades at $10.22 (market cap $72.26M), while Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 1154.6× Carparts.Com Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Carparts.Com Inc pays none. Which is the better fit depends on your goals.
| PRTS | REGN | |
|---|---|---|
Market Cap | $72.26M | $83.43B |
Sector | Consumer Cyclical | Health |
52-Week High | $10.00 | $852.03 |
52-Week Low | $3.88 | $555.51 |
Enterprise Value | $85.23M | $78.14B |
Dividend Yield | — | 0.46% |
Signals from Pluang's Aura AI — not financial advice
CarParts.com (PRTS) trades at $9.50, up 2.15% with strong technical momentum and bullish moving average signals. The company shows improving quarterly earnings performance with three consecutive beats, though it remains unprofitable with negative margins. Recent developments include a new $25 million credit facility and Nasdaq compliance restoration, while analyst sentiment leans positive with 60% buy ratings.
The outlook suggests cautious optimism given improving earnings trajectory and technical strength, but significant risks persist from sustained losses, negative cash flow, and competitive pressures. Investment appeal hinges on the company's ability to translate revenue stabilization into profitability while managing operational challenges in the automotive e-commerce sector.
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Trailing returns across standard periods
Latest headlines on both assets
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →